Matthew C Nali, Meng Zhen Larsen, Zhuoran Li, Jiawei Li, Douglas R Roehler, Vanessa Mallory, Tim K Mackey
{"title":"对在线市场上美国大麻产品健康益处声明的探索性分析。","authors":"Matthew C Nali, Meng Zhen Larsen, Zhuoran Li, Jiawei Li, Douglas R Roehler, Vanessa Mallory, Tim K Mackey","doi":"10.1111/add.70177","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>Cannabis-derived products (CDPs), including cannabidiol (CBD) and tetrahydrocannabinol (THC) products, are widely diverse and readily available through physical and online retail channels in the United States (US) marketplace and may also include claims of treating or providing benefit for health issues. This study aimed to systematically classify the various types of health benefit claim(s) present on CDP listings based on publicly available online marketplace data.</p><p><strong>Design: </strong>Exploratory analysis to identify health benefit claims.</p><p><strong>Setting and cases: </strong>A total of 624 805 unique CDPs sold in the US on Leafly and Weedmaps, cannabis online marketplace service platforms.</p><p><strong>Measurements: </strong>This exploratory study was conducted in four phases: (1) data mining of cannabis e-commerce websites Weedmaps and Leafly for product listings in the US; (2) data filtering, text matching and content coding to identify types of advertised health benefit(s) made; (3) analysis on consumer-generated product reviews for sentiment toward advertised health benefit(s); and (4) ANOVA was used to test differences in mean number of health benefit claims based on product characteristic of route-of-administration (RoA).</p><p><strong>Findings: </strong>A total of 624 805 unique US CDP sales listings from Leafly (n = 50 951) and Weedmaps (n = 573 854) were analyzed. CDP listings with a specific health benefit claim(s) were detected in 998 (1.9%) Leafly and 25 671 (4.47%) Weedmaps CDP listings. The top 5 advertised health benefits were treatment of mood disorders, general discomfort, general wellness, sleep disorders and chronic conditions. Among consumer reviews, 295 (4.6% of consumer reviews from products that advertised health benefit(s)) expressed sentiment toward CDP addressing their health issue with 82.4% being positive, 14.6% negative and 3.1% neutral. We also observed statistically significant differences between RoA and frequency of health benefit claims among those with at least one health benefit claim, with multisystem products (>1RoA) generally having a higher number of average health benefit claims compared with other RoAs.</p><p><strong>Conclusions: </strong>Over 26 000 cannabis-derived products listed on two popular US cannabis online marketplaces have at least one health benefit claim.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exploratory analysis of United States-based cannabis product health benefit claims on online marketplaces.\",\"authors\":\"Matthew C Nali, Meng Zhen Larsen, Zhuoran Li, Jiawei Li, Douglas R Roehler, Vanessa Mallory, Tim K Mackey\",\"doi\":\"10.1111/add.70177\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>Cannabis-derived products (CDPs), including cannabidiol (CBD) and tetrahydrocannabinol (THC) products, are widely diverse and readily available through physical and online retail channels in the United States (US) marketplace and may also include claims of treating or providing benefit for health issues. This study aimed to systematically classify the various types of health benefit claim(s) present on CDP listings based on publicly available online marketplace data.</p><p><strong>Design: </strong>Exploratory analysis to identify health benefit claims.</p><p><strong>Setting and cases: </strong>A total of 624 805 unique CDPs sold in the US on Leafly and Weedmaps, cannabis online marketplace service platforms.</p><p><strong>Measurements: </strong>This exploratory study was conducted in four phases: (1) data mining of cannabis e-commerce websites Weedmaps and Leafly for product listings in the US; (2) data filtering, text matching and content coding to identify types of advertised health benefit(s) made; (3) analysis on consumer-generated product reviews for sentiment toward advertised health benefit(s); and (4) ANOVA was used to test differences in mean number of health benefit claims based on product characteristic of route-of-administration (RoA).</p><p><strong>Findings: </strong>A total of 624 805 unique US CDP sales listings from Leafly (n = 50 951) and Weedmaps (n = 573 854) were analyzed. CDP listings with a specific health benefit claim(s) were detected in 998 (1.9%) Leafly and 25 671 (4.47%) Weedmaps CDP listings. The top 5 advertised health benefits were treatment of mood disorders, general discomfort, general wellness, sleep disorders and chronic conditions. Among consumer reviews, 295 (4.6% of consumer reviews from products that advertised health benefit(s)) expressed sentiment toward CDP addressing their health issue with 82.4% being positive, 14.6% negative and 3.1% neutral. We also observed statistically significant differences between RoA and frequency of health benefit claims among those with at least one health benefit claim, with multisystem products (>1RoA) generally having a higher number of average health benefit claims compared with other RoAs.</p><p><strong>Conclusions: </strong>Over 26 000 cannabis-derived products listed on two popular US cannabis online marketplaces have at least one health benefit claim.</p>\",\"PeriodicalId\":109,\"journal\":{\"name\":\"Addiction\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Addiction\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/add.70177\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/add.70177","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Exploratory analysis of United States-based cannabis product health benefit claims on online marketplaces.
Background and aims: Cannabis-derived products (CDPs), including cannabidiol (CBD) and tetrahydrocannabinol (THC) products, are widely diverse and readily available through physical and online retail channels in the United States (US) marketplace and may also include claims of treating or providing benefit for health issues. This study aimed to systematically classify the various types of health benefit claim(s) present on CDP listings based on publicly available online marketplace data.
Design: Exploratory analysis to identify health benefit claims.
Setting and cases: A total of 624 805 unique CDPs sold in the US on Leafly and Weedmaps, cannabis online marketplace service platforms.
Measurements: This exploratory study was conducted in four phases: (1) data mining of cannabis e-commerce websites Weedmaps and Leafly for product listings in the US; (2) data filtering, text matching and content coding to identify types of advertised health benefit(s) made; (3) analysis on consumer-generated product reviews for sentiment toward advertised health benefit(s); and (4) ANOVA was used to test differences in mean number of health benefit claims based on product characteristic of route-of-administration (RoA).
Findings: A total of 624 805 unique US CDP sales listings from Leafly (n = 50 951) and Weedmaps (n = 573 854) were analyzed. CDP listings with a specific health benefit claim(s) were detected in 998 (1.9%) Leafly and 25 671 (4.47%) Weedmaps CDP listings. The top 5 advertised health benefits were treatment of mood disorders, general discomfort, general wellness, sleep disorders and chronic conditions. Among consumer reviews, 295 (4.6% of consumer reviews from products that advertised health benefit(s)) expressed sentiment toward CDP addressing their health issue with 82.4% being positive, 14.6% negative and 3.1% neutral. We also observed statistically significant differences between RoA and frequency of health benefit claims among those with at least one health benefit claim, with multisystem products (>1RoA) generally having a higher number of average health benefit claims compared with other RoAs.
Conclusions: Over 26 000 cannabis-derived products listed on two popular US cannabis online marketplaces have at least one health benefit claim.
期刊介绍：
Addiction publishes peer-reviewed research reports on pharmacological and behavioural addictions, bringing together research conducted within many different disciplines.
Its goal is to serve international and interdisciplinary scientific and clinical communication, to strengthen links between science and policy, and to stimulate and enhance the quality of debate. We seek submissions that are not only technically competent but are also original and contain information or ideas of fresh interest to our international readership. We seek to serve low- and middle-income (LAMI) countries as well as more economically developed countries.
Addiction’s scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
